Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

BioSim™ anti-Bevacizumab II (Human) ELISA Kit

A Sandwich ELISA kit for the qualitative measurement of antibodies to Bevacizumab in human serum or plasma samples
Catalog #: E4874

Product Details

Cat # +Size E4874-100
Size 96 assays
Detection Method Absorbance (450 nm)
Species Reactivity Human
Applications This Sandwich ELISA kit is used for in vitro qualitative determination of antibodies to Bevacizumab in human serum and plasma samples
Features & Benefits • Assay Precision: Intra-Assay and Inter-Assay CV < 30%
• For in vitro qualitative determination of antibodies to Bevacizumab in human serum and plasma samples
• Cross Reactivity: Except for Bevacizumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins
Kit Components • Microtiter Plate
• Positive Control
• Negative Control
• Assay Buffer
• HRP-conjugate Probe
• TMB substrate (Avoid light)
• Stop Solution
• Wash buffer (20X)
• Plate sealers
Storage Conditions 4°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.


Bevacizumab is a humanized IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor A (VEGF-A) and prevents its binding to cell surface receptors. VEGFA is a pro-angiogenic protein that promotes migration, proliferation, and survival of endothelial cells. Binding of the antibody to VEGFA results in decreased neovascularization, thus limiting blood supply to the tumors and ultimately causes shrinkage of the tumor. The antibody is approved to treat advanced stages of cancer such as colorectal cancer, non-small cell lung cancer, metastatic breast cancer, and glioblastoma multiforme. BioSim™ anti-Bevacizumab ELISA kit has been specifically developed to qualitatively determine antibodies to Bevacizumab in human serum and plasma samples. The ELISA kit is based on the sandwich principle. Controls and samples (serum and plasma) are incubated in the microtiter plate coated with the drug Bevacizumab. After incubation, the wells are washed and the enzymatic activity is detected by the addition of chromogen-substrate. The enzyme-substrate reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies specific for Bevacizumab present in the samples and controls. The qualitative test results can be evaluated using cut-off value.

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.